Skip to main content
SpringerLink
Log in

Cardiac Mitochondria and Heart Failure: The Chicken or the Egg?

  • Chapter
Annual Update in Intensive Care and Emergency Medicine 2011

Part of the book series: Annual Update in Intensive Care and Emergency Medicine 2011 ((AUICEM,volume 1))

  • 2109 Accesses

Abstract

Current medical therapies for heart failure are aimed at suppressing the neurohormonal activation (e.g., angiotensin converting enzyme [ACE] inhibitors, angiotensin II receptor antagonists, beta-adrenergic receptor antagonists, aldosterone receptor antagonists) and/or treating fluid volume overload and hemodynamic symptoms (diuretics, digoxin, inotropic agents) [1, 2]. Evidence suggests that intense suppression of the neurohormonal systems does not provide further benefit compared with more modest therapy. There is a need for novel therapies for heart failure that are independent of the neurohormonal axis and can improve cardiac performance and prevent the progression of heart failure and heart remodeling [3]. Modulation of mitochondrial metabolism and the oxidative status of the myocardium may represent a new approach to the treatment of heart failure and could work additively with standard medical therapy while not exerting negative hemodynamic effects [4].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. McMurray JJ, Pfeffer MA (2005) Heart Failure. Lancet 365: 1877–1889

    Article  PubMed  Google Scholar 

  2. Triposkiadis F, Parissis JT, Starling RC, Skoularigis J, Louridas G (2009) Current drugs and medical treatment algorithms in the management of acute decompensated heart failure. Expert Opin Investig Drugs 18: 695–707

    Article  PubMed  CAS  Google Scholar 

  3. Ormerod JOM, Ashrafian H, Frenneaux MP (2008) Impaired energetics in heart failure. A new therapeutic target. Pharmacology & Therapeutics 119: 264–274

    Article  CAS  Google Scholar 

  4. Fragasso G, Salerno A, Spoladore R, Bassanelli G, Arioli F, Margonato A (2008) Metabolic therapy of heart failure. Curr Pharm Des 14: 2582–2591

    Article  PubMed  CAS  Google Scholar 

  5. Ingwall JS (2009) Energy metabolism in heart failure and remodelling. Cardiovasc Res 81: 412–419

    Article  PubMed  CAS  Google Scholar 

  6. Neubauer S (2007) The failing heart: an engine out of fuel. N Engl J Med 356: 1140–1151

    Article  PubMed  Google Scholar 

  7. Abozguia K, Shivu GN, Ahmed I, Phan TT, Frenneaux MP (2009) The heart metabolism: pathophysiological aspects in ischemia and failure. Current Pharmaceutical Design 15: 827–835

    Article  PubMed  CAS  Google Scholar 

  8. Bessman SP, Geiger PJ (1981) Transport of energy in muscle: the phosphocreatine shuttle. Science 211: 448–452

    Article  PubMed  CAS  Google Scholar 

  9. Neubauer S, Horn M, Cramer M, et al (1997) Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 96: 2190–2196

    PubMed  CAS  Google Scholar 

  10. Conway MA, Allis J, Ouwerkerk R, Niioka T, Rajagopalan B, Radda GK (1991) Detection of low phosphocreatine to ATP ratio in failing hypertrophied human myocardium by 31P magnetic resonance spectroscopy. Lancet 338: 973–976

    Article  PubMed  CAS  Google Scholar 

  11. Stanley WC, Recchia FA, Lopaschuk GD (2005) Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 85: 1093–1129

    Article  PubMed  CAS  Google Scholar 

  12. Luptak I, Yan J, Cui L, Jain M, Liao R, Tian R (2007) Long-term effects of increased glucose entry on mouse hearts during normal aging and ischemic stress. Circulation 116: 901–909

    Article  PubMed  CAS  Google Scholar 

  13. Madrazo JA, Kelly DP (2008) The PPAR trio: regulators of myocardial energy metabolism in health and disease. J Mol Cell Cardiol 44: 968–975

    Article  PubMed  CAS  Google Scholar 

  14. Sihag S, Cresci S, Li AY, Sucharov CC, Lehman JJ (2009) PGC-lalpha and ERRalpha target gene downregulation is a signature of the failing human heart. J Mol Cell Cardiol 46: 201–212

    Article  PubMed  CAS  Google Scholar 

  15. Opie LH (2004) The metabolic vicious cycle in heart failure. Lancet 364: 1733–1734

    Article  PubMed  Google Scholar 

  16. Ashrafian H, Frenneaux MP, Opie LH (2007) Metabolic mechanisms in heart failure. Circulation 116: 434–448

    Article  PubMed  CAS  Google Scholar 

  17. Nikolaidis LA, Sturzu A, Stolarski C, Elahi D, Shen YT, Shannon RP (2004) The development of myocardial insulin resistance in conscious dogs with advanced dilated cardiomyopathy. Cardiovasc Res 61: 297–306

    Article  PubMed  CAS  Google Scholar 

  18. Fragasso G (2007) Inhibition of free fatty acids metabolism as a therapeutic target in patients with heart failure. Int J Clin Pract 61: 603–610

    Article  PubMed  CAS  Google Scholar 

  19. Tuunanen H, Engblom E, Naum A, et al (2006) Free fatty acid depletion acutely decreases cardiac work and efficiency in cardiomyopathic heart failure. Circulation 114: 2130–2137

    Article  PubMed  CAS  Google Scholar 

  20. Ashrafian H, Horowitz JD, Frenneaux MP (2007) Perhexiline. Cardiovasc Drug Rev 25: 76–97

    Article  PubMed  CAS  Google Scholar 

  21. Fragasso G, Spoladore R, Cuko A, Palloshi A (2007) Modulation of fatty acids oxidation in heart failure by selective pharmacological inhibition of 3-ketoacyl coenzyme-A thiolase. Curr Clin Pharmacol 2: 190–196

    Article  PubMed  CAS  Google Scholar 

  22. Lopaschuk GD (2006) Optimizing cardiac fatty acid and glucose metabolism as an approach to treating heart failure. Semin Cardiothorac Vase Anesth 10: 228–230

    Article  Google Scholar 

  23. Marin-Garcia J, Goldenthal MJ, Moe GW (2001) Mitochondrial pathology in cardiac failure. Cardiovasc Res 49: 17–26

    Article  PubMed  CAS  Google Scholar 

  24. Di Lisa F, Kaludercic N, Carpi A, Menabò R, Giorgio M (2009) Mitochondrial pathways for ROS formation and myocardial injury: the relevance of p66(Shc) and monoamne oxidase. Basic Res Cardiol 104: 131–139

    Article  PubMed  Google Scholar 

  25. Tsutsui H (2001) Oxidative stress in heart failure: the role of mitochondria. Internal Medicine 40: 1177–1182

    Article  PubMed  CAS  Google Scholar 

  26. Hughes G, Murphy MP, Ledgerwood EC (2005) Mitochondrial reactive oxygen species regulate the temporal activation of nuclear factor kappaB to modulate tumour necrosis factor-induced apoptosis: evidence from mitochondria-targeted antioxidants. Biochem J 389: 83–89

    Article  PubMed  CAS  Google Scholar 

  27. Javadov S, Karmazyn M, Escobales N (2009) Mitochondrial permeability transition pore opening as a promising therapeutic target in cardiac diseases. J Pharmac Exp Ther 330: 670–678

    Article  CAS  Google Scholar 

  28. Wagner M, Siddiqui MA (2009) Signaling networks regulating cardiac myocyte survival and death. Curr Opin Investig Drugs 10: 928–937

    PubMed  CAS  Google Scholar 

  29. Tsutsui H, Kinugawa S, Matsushima S (2009) Mitochondrial oxidative stress and dysfunction in myocardial remodelling. Cardiovasc Res 81: 449–456

    Article  PubMed  CAS  Google Scholar 

  30. Huss JM, Kelly DP (2005) Mitochondrial energy metabolism in heart failure: a question of balance. J Clin Invest 115: 547–555

    PubMed  CAS  Google Scholar 

  31. Jassem W, Fuggle SV, Rela M, Koo DDH, Heaton ND (2002) The role of mitochondria in ischemia/reperfusion injury. Transplantation 73: 493–499

    Article  PubMed  CAS  Google Scholar 

  32. Zaugg M, Schaub MC, Foex P (2004) Myocardial injury and its prevention in the perioperative setting. Br J Anaesth 93: 21–33

    Article  PubMed  CAS  Google Scholar 

  33. Bolli R (1998) Causative role of oxyradicals in myocardial stunning: a proven hypothesis. A brief review of the evidence demonstrating a major role of reactive oxygen species in several forms of postischemic dysfunction. Basic Res Cardiol 93: 156–162

    Article  PubMed  CAS  Google Scholar 

  34. Chen Z, Siu B, Ho YS, et al (1998) Overexpression of MnSOD protects against myocardial ischemia/reperfusion injury in transgenic mice. J Mol Cell Cardiol 30: 2281–2289

    Article  PubMed  CAS  Google Scholar 

  35. Suzuki K, Murtuza B, Sammut IA, et al (2002) Heat shock protein 72 enhances manganese superoxide dismutase activity during myocardial ischemia-reperfusion injury, associated with mitochondrial protection and apoptosis reduction. Circulation 106(Suppl 1): 270–276

    Google Scholar 

  36. Tsutsui H, Ide T, Kinugawa S (2006) Mitochondrial oxidative stress, DNA damage, and heart failure. Antioxid Redox Signal 8: 1737–1744

    Article  PubMed  CAS  Google Scholar 

  37. Shiomi T, Tsutsui H, Matsusaka H, et al (2004) Overexpression of glutathione peroxidase prevents left ventricular remodeling and failure after myocardial infarction in mice. Circulation 109: 544–549

    Article  PubMed  CAS  Google Scholar 

  38. Klawitter PF, Murray HN, Clanton TL, Angelos MG (2002) Reactive oxygen species generated during myocardial ischemia enable energetic recovery during reperfusion. Am J Physiol Heart Circ Physiol 283: 1656–1661

    Google Scholar 

  39. Sheeran FL, Pepe S (2006) Energy deficiency in the failing heart: linking increased reactive oxygen species and disruption of oxidative phosphorilation rate. Biochim Biophys Acta 1757: 543–552

    Article  PubMed  CAS  Google Scholar 

  40. Carlucci F, Tabucchi A, Biagioli B, et al (2002) Cardiac surgery: myocardial energy balance, antioxidant status and endothelial function after ischemia-reperfusion. Biomed Pharmacother 56: 483–491

    Article  PubMed  CAS  Google Scholar 

  41. Ferrari R, Alfieri O, Curello S, et al (1990) Occurrence of oxidative stress during reperfusion of the human heart. Circulation 81: 201–211

    PubMed  CAS  Google Scholar 

  42. Marczin N, El-Hbashi N, Hoare GS, Bundy RE, Yacoub M (2003) Antioxidants in myocardial ischemia-reperfusion injury: therapeutic potential and basic mechanisms. Archives of Biochemistry and Biophysics 420: 222–236

    Article  PubMed  CAS  Google Scholar 

  43. Biagioli B, Scolletta S, Marchetti L, Tabucchi A, Carlucci F (2003) Relationships between hemodynamic parameters and myocardial energy and antioxidant status in heart transplantation. Biomed Pharmacother 57: 156–162

    Article  PubMed  CAS  Google Scholar 

  44. Scolletta S, Carlucci F, Biagioli B, et al (2007) NT-proBNP changes, oxidative stress, and energy status of hypertrophic myocardium following ischemia/reperfusion injury. Biomed Pharmacother 61: 160–166

    Article  PubMed  CAS  Google Scholar 

  45. Boku N, Tanoue Y, Kajihara N, Eto M, Masuda M, Morita S (2006) A comparative study of cardiac preservation with Celsior or University of Wisconsin solution with or without prior administration of cardioplegia. J Heart Lung Transplant 25: 219–225

    Article  PubMed  Google Scholar 

  46. Kloner RA (2009) Clinical application of remote ischemic preconditioning. Circulation 119: 776–778

    Article  PubMed  Google Scholar 

  47. Baines CP (2009) The mitochondrial permeability transition pore and ischemia-reperfusion injury. Basic Res Cardiol 104: 181–188

    Article  PubMed  CAS  Google Scholar 

  48. Gross GJ, Peart JN (2003) KATP channels and myocardial preconditioning: an update. Am J Physiol Heart Circ Physiol 285: 921–930

    Google Scholar 

  49. Cleveland JC Jr, Meldrum DR, Cain BS, Banerjee A, Harken AH (1997) Oral sulfonylurea hypoglycaemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited. Circulation 96: 29–32

    CAS  Google Scholar 

  50. Frässdorf J, De Hert S, Schlack W (2009) Anaesthesia and myocardial ischaemia/reperfusion injury. Br J Anaesth 103: 89–98

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery and Bioengineering Unit of Cardiothoracic Anesthesia and Intensive Care, University of Siena, Viale Bracci 1, 53100, Siena, Italy

    S. Scolletta, B. Biagioli & P. Giomarelli

Authors
  1. S. Scolletta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Biagioli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. Giomarelli
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Intensive Care, Erasme Hospital, Université libre de Bruxelles, Route de Lennik 808, B-1070, Brussels, Belgium

    Jean-Louis Vincent (Head) (Head)

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media LLC

About this chapter

Cite this chapter

Scolletta, S., Biagioli, B., Giomarelli, P. (2011). Cardiac Mitochondria and Heart Failure: The Chicken or the Egg?. In: Vincent, JL. (eds) Annual Update in Intensive Care and Emergency Medicine 2011. Annual Update in Intensive Care and Emergency Medicine 2011, vol 1. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18081-1_18

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-18081-1_18

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-18080-4

  • Online ISBN: 978-3-642-18081-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation